Medically Reviewed by Dr. Michael Nguyen, PharmD, BSPharm — Functional Medicine Pharmacist, Sterile Compounding Specialist, PCCA & NHIA Certified. 27+ years of clinical experience in peptide therapy and metabolic health.
Key Takeaways
- Ozempic (1 mg/week) and Wegovy (2.4 mg/week) contain the same molecule — semaglutide — but carry different FDA-approved indications and very different price tags, often $900–$1,300/month without insurance.
- The STEP 1 trial showed Wegovy produced an average 14.9% body weight reduction over 68 weeks — meaningful but achievable only for patients who can afford it or secure coverage.
- Compounded semaglutide, when prepared by an FDA-registered 503B outsourcing facility, contains the identical active ingredient and can cost $150–$350/month — a fraction of brand pricing.
- The right choice depends on your insurance situation, clinical indication, and whether you have access to a licensed provider who can supervise dosing and monitoring.
- Lab work — HbA1c, fasting insulin, lipid panel, thyroid — is essential before starting any semaglutide form.
Semaglutide is now one of the most-prescribed medications in the United States, yet the majority of people who want it can’t access it — or can’t afford it. Three versions exist in the market: Ozempic, approved for type 2 diabetes; Wegovy, approved for chronic weight management; and compounded semaglutide, made by licensed pharmacy facilities at a fraction of the cost. They all work through the same GLP-1 receptor mechanism. So why does it matter which one you use, and how do you even get access to the most affordable option legally? This guide breaks it all down.
[INTERNAL-LINK: learn how semaglutide works at the receptor level → deep-dive semaglutide mechanism of action article]
What’s Actually the Difference Between Ozempic, Wegovy, and Compounded Semaglutide?
In 2021, the FDA approved semaglutide 2.4 mg (Wegovy) for chronic weight management — a higher dose than the 1 mg Ozempic approved for type 2 diabetes in 2017. Both are subcutaneous injections of the same active molecule, manufactured by Novo Nordisk. Compounded semaglutide uses the identical API (active pharmaceutical ingredient) but is prepared by licensed compounding pharmacies rather than the brand manufacturer. The difference is regulatory designation and dose titration schedule, not the molecule itself.
What that means practically: a patient paying $1,200/month for Wegovy is buying the same semaglutide peptide as someone paying $200/month through a compounding pharmacy. The brand premium covers Novo Nordisk’s marketing, patent protection, and distribution infrastructure — not a better version of the drug.
[UNIQUE INSIGHT] Most patients and even some providers don’t realize the FDA shortage designation that opened the door for compounded semaglutide legally expired in early 2025 — but access hasn’t disappeared. Compounding remains legal under specific conditions, including patient-specific prescriptions from licensed providers and production by registered facilities. Understanding the current legal landscape is essential before sourcing anything.
FDA Approval Differences: Why the Indication Matters
Ozempic carries FDA approval for glycemic control in adults with type 2 diabetes as an adjunct to diet and exercise. Wegovy carries FDA approval for chronic weight management in adults with a BMI ≥30, or ≥27 with at least one weight-related comorbidity (hypertension, dyslipidemia, type 2 diabetes, sleep apnea). These are separate NDA submissions with separate label claims — even though the molecule is the same.
Why does this matter for you? Insurance coverage is tied to indication. A patient using Ozempic off-label for weight loss will likely find it rejected by their insurer for that purpose. A patient prescribed Wegovy for obesity who also has type 2 diabetes may find Medicare Part D won’t cover it because Medicare excludes coverage for anti-obesity drugs under most circumstances (a policy many advocates are working to change).
Approved Dosing Schedules
Both medications use a dose-escalation protocol to minimize gastrointestinal side effects:
| Week Range | Ozempic Dose | Wegovy Dose |
|---|---|---|
| Weeks 1–4 | 0.25 mg/week | 0.25 mg/week |
| Weeks 5–8 | 0.5 mg/week | 0.5 mg/week |
| Weeks 9–12 | 1 mg/week (maintenance) | 1 mg/week |
| Weeks 13–16 | 2 mg/week (optional) | 1.7 mg/week |
| Week 17+ | 2 mg/week | 2.4 mg/week (maintenance) |
Compounded formulations follow the same dose-escalation principle, but the exact schedule is tailored by your provider based on your tolerance and metabolic response — which is one of the genuine advantages of working with a functional medicine or metabolic health provider rather than a retail pharmacy model.
What Does the Clinical Evidence Actually Show?
In 2021, the New England Journal of Medicine published the STEP 1 trial results: adults with obesity receiving semaglutide 2.4 mg/week lost an average of 14.9% of body weight over 68 weeks, compared to 2.4% in the placebo group (Wilding et al., NEJM, 2021). That’s a clinically significant difference — patients averaging about 15 pounds of weight loss per 100 pounds of body weight.
But here’s what the trial doesn’t tell you: STEP 1 participants received intensive lifestyle counseling alongside the medication. Real-world results without structured support tend to be lower. A 2023 analysis published in Obesity found real-world semaglutide users achieved 8–10% body weight reduction at 12 months — still meaningful, but not the headline 15% (Wilding et al., Obesity, 2023).
Clinical Insight: In clinical practice with patients on compounded semaglutide, results at 6 months often parallel the STEP trial data when patients receive metabolic monitoring, lab-guided dosing, and dietary support alongside the injection — not just the medication alone. The molecule is the same; the outcome depends heavily on the clinical context surrounding it.
The STEP 5 trial followed participants for 104 weeks and found 15.2% weight loss — suggesting benefits sustain with continued use (Garvey et al., Lancet Diabetes & Endocrinology, 2022). Critically, the STEP 4 trial showed that patients who discontinued semaglutide regained two-thirds of their lost weight within a year — which has major implications for how you think about long-term access and cost sustainability.
Cost Comparison: What Are You Actually Paying?
The price gap between brand and compounded semaglutide is one of the most striking disparities in modern medicine. In 2025, Wegovy’s list price reached approximately $1,349/month, while Ozempic listed at around $935/month. Compounded semaglutide from a licensed 503B facility typically runs $150–$350/month depending on dose. Here’s how those numbers look side by side:
Monthly Cost Comparison: Semaglutide Forms (2025 Estimates)
~$1,349/mo
~$935/mo
$150–$350/mo
Sources: GoodRx list prices 2025; compounded pricing varies by provider and facility. List prices before insurance or manufacturer coupons.
With insurance, the calculus shifts. Patients with commercial insurance who qualify for Wegovy’s manufacturer coupon (Novo Nordisk’s NovoCare program) can access it for as low as $0–$25/month in some cases. But Medicare and most Medicaid plans don’t cover anti-obesity medications, leaving a large portion of the population with obesity paying full list price — or looking for alternatives.
Get Your Pre-Treatment Labs
Order HbA1c, fasting insulin, lipid panel, and thyroid function through Private MD Labs before starting semaglutide. Use code DRMICHAELNGUYEN for 15% off.
Is Compounded Semaglutide Legal? Understanding the Current FDA Status
This is the question patients ask most — and the answer requires precision. In 2022 and 2023, the FDA placed semaglutide on its drug shortage list, which allowed licensed compounding pharmacies to produce it legally under Section 503A and 503B of the Federal Food, Drug, and Cosmetic Act. In February 2025, the FDA removed semaglutide from the shortage list, which triggered a compliance deadline for compounders to wind down shortage-based production.
However, compounding didn’t become illegal. What changed was the basis for authorization. Going forward:
- 503A pharmacies (traditional compounders) can still prepare semaglutide for individual patients with a valid prescription, when a specific medical need exists that the commercial product doesn’t meet — such as a patient requiring a different dose, diluent, or delivery format.
- 503B outsourcing facilities (higher-regulation, FDA-registered) operate under stricter standards and can compound under their own protocols without a patient-specific prescription, but face ongoing FDA scrutiny post-shortage.
- What’s prohibited: Bulk compounding of semaglutide copies that are essentially identical to Wegovy or Ozempic without a patient-specific clinical rationale, and production by facilities not registered with the FDA.
The FDA issued warning letters in 2024 and 2025 to facilities found compounding non-compliant versions. The key for patients: access compounded semaglutide only through a licensed clinical provider who can write a valid individualized prescription and who sources from a verified, FDA-registered 503B facility or a compliant 503A pharmacy.
According to the FDA’s 2025 guidance on 503B outsourcing facilities, compounded semaglutide remains accessible when prepared by registered facilities under appropriate clinical oversight and patient-specific prescriptions. The FDA’s primary enforcement target is bulk, non-individualized compounding — not provider-supervised patient access through legitimate pharmacy channels (FDA, Outsourcing Facility Information, 2025).
Full Comparison: Ozempic vs Wegovy vs Compounded Semaglutide
| Feature | Ozempic | Wegovy | Compounded |
|---|---|---|---|
| FDA Indication | Type 2 diabetes | Chronic weight management | Per provider/prescription |
| Maintenance Dose | 1–2 mg/week | 2.4 mg/week | Individualized (0.25–2.4 mg) |
| Monthly Cost (est.) | ~$935 list | ~$1,349 list | $150–$350 |
| Insurance Coverage | Often for T2D; varies | Commercial only; not Medicare | Not covered |
| Manufacturer | Novo Nordisk | Novo Nordisk | Licensed 503A/503B pharmacy |
| Availability | Retail pharmacy | Retail pharmacy | Through licensed provider |
| Pen/Device | Pre-filled auto-injector | Pre-filled auto-injector | Vial + syringe (typically) |
| Clinical Monitoring | Through prescribing physician | Through prescribing physician | Through supervising provider |
Who Should Choose Which Option?
The right form isn’t about brand prestige — it’s about your clinical situation, insurance coverage, and access to monitoring. Here’s a practical framework:
Choose Ozempic if:
- You have type 2 diabetes and your insurer covers Ozempic for that indication
- Your HbA1c is above 7% and glycemic control is the primary goal alongside weight loss
- You prefer the convenience of a pre-filled, FDA-approved pen device
- Your provider is comfortable prescribing within the approved T2D label
Choose Wegovy if:
- You have obesity (BMI ≥30) or overweight (BMI ≥27) with a qualifying comorbidity and no diabetes
- You have commercial insurance that covers Wegovy and you’ve confirmed prior authorization
- You want the highest FDA-approved dose (2.4 mg) with the full clinical trial evidence base behind it
- Cost is manageable through coverage or the Novo Nordisk savings program
Choose Compounded Semaglutide if:
- You don’t have insurance coverage for either brand and cost is the barrier to treatment
- You want individualized dosing with close provider oversight
- You’re working with a functional or metabolic medicine provider who can tailor the protocol to your labs and response
- You’ve verified your provider sources from an FDA-registered 503B facility or a compliant 503A pharmacy
A 2024 analysis by the USC Schaeffer Center for Health Policy found that compounded semaglutide could dramatically expand access for the 100+ million Americans with obesity who lack commercial insurance coverage for Wegovy — with cost as the single largest barrier to initiating treatment (USC Schaeffer Center, 2024). For these patients, a provider-supervised compounded protocol isn’t a workaround — it’s often the only realistic path to evidence-based care.
Access Compounded Semaglutide Through a Provider
Metabolic Regen MD offers compounded semaglutide under licensed provider oversight with full metabolic workup and personalized dosing — at a fraction of brand-name cost.
How to Access Compounded Semaglutide Legally Through a Licensed Provider
The process for accessing compounded semaglutide legally is straightforward when you work with the right clinical team. Here’s what it looks like in practice:
Step 1: Complete a Metabolic Baseline Workup
Before any semaglutide prescription — compounded or brand — you need baseline labs. At minimum: HbA1c, fasting insulin, fasting glucose, lipid panel (total cholesterol, LDL, HDL, triglycerides), thyroid function (TSH, free T3, free T4), and a comprehensive metabolic panel. These labs establish your clinical picture, rule out contraindications (personal or family history of medullary thyroid carcinoma or MEN2 syndrome), and give your provider a baseline to track your response.
[INTERNAL-LINK: what labs to order before starting a GLP-1 → pre-GLP-1 lab testing guide]
Step 2: Work With a Licensed Provider Who Specializes in Metabolic Health
Compounded semaglutide requires a valid, individualized prescription from a licensed prescriber. That provider also needs to have a clinical rationale for the compound rather than the commercially available product. A functional medicine physician, metabolic health specialist, or clinical pharmacist practicing in prescriptive authority states can fill this role. Telehealth platforms have expanded access significantly — but quality varies widely. Look for providers who review your labs before prescribing, not platforms that issue prescriptions after a 5-minute questionnaire.
Step 3: Verify the Pharmacy Source
Ask your provider directly: is this sourced from an FDA-registered 503B outsourcing facility, or a 503A compounding pharmacy? What are their quality controls — third-party sterility testing, potency verification, endotoxin testing? Legitimate compounders provide certificates of analysis (CoA) for each batch. If your provider can’t answer these questions, that’s a signal to find a different provider.
Step 4: Establish a Monitoring Protocol
Semaglutide isn’t a set-it-and-forget-it medication. You need follow-up labs at 3 months (repeat HbA1c and metabolic panel), monitoring for side effects (nausea, vomiting, gastroparesis, pancreatitis risk), and periodic reassessment of dose. A good provider builds this into the protocol from day one.
Sourcing Compounded Semaglutide for Research
Elite Biologix supplies GLP receptor agonist research compounds at verified purity for qualified laboratory and research environments. Not listed publicly — inquire directly.
What About Side Effects — Are They Different Across Forms?
The side effect profile of semaglutide is tied to the molecule and the dose, not the manufacturer. GI effects — nausea, vomiting, diarrhea, constipation — are the most common across all three forms and are dose-dependent. They’re most pronounced during dose escalation and typically improve once you reach maintenance dosing. In the STEP 1 trial, 44% of participants reported nausea and 24% reported vomiting (Wilding et al., NEJM, 2021).
Where differences can emerge with compounded formulations: purity and formulation quality. A poorly formulated compound — wrong excipients, inadequate sterility, inaccurate potency — can produce unpredictable side effects or subtherapeutic results. This is why facility verification matters. A legitimate 503B facility produces compounded semaglutide with the same sterility and potency standards as a pharmaceutical manufacturer.
Serious adverse events — pancreatitis, gallbladder disease, hypoglycemia in patients on concurrent insulin secretagogues — are class effects of GLP-1 receptor agonists and apply equally across all three forms. Patients with a personal or family history of medullary thyroid carcinoma or MEN2 should not use any semaglutide product.
[INTERNAL-LINK: tirzepatide vs semaglutide — what’s the actual clinical difference → tirzepatide deep dive article]
Frequently Asked Questions
Is compounded semaglutide as effective as Wegovy or Ozempic?
When sourced from a verified 503B facility or compliant 503A pharmacy, compounded semaglutide contains the identical active ingredient at equivalent potency. Clinical outcomes depend on dose, adherence, lifestyle factors, and provider oversight — not on whether the product has a brand name. Patients achieving equivalent doses under provider supervision report similar outcomes to branded users.
Can I use Ozempic for weight loss even if I don’t have diabetes?
Yes, but it’s off-label use. Ozempic’s FDA approval is for type 2 diabetes management. Using it for weight loss without a diabetes diagnosis is legal and clinically supported by the science, but insurance is unlikely to cover it for that indication. Many providers prescribe it off-label for weight management, particularly at the 2 mg dose range.
Will my insurance cover Wegovy?
Commercial insurance coverage for Wegovy varies significantly by plan. In 2024, roughly 30% of commercially insured patients had Wegovy coverage, according to KFF Health Tracking data. Medicare does not cover anti-obesity drugs. If you have employer-sponsored insurance, check your formulary directly and ask about prior authorization requirements, which typically require documented BMI ≥30 or ≥27 with comorbidities.
What happens if I stop taking semaglutide?
The STEP 4 trial showed that patients who stopped semaglutide after 68 weeks of treatment regained, on average, two-thirds of their lost weight within 52 weeks of discontinuation (Rubino et al., NEJM, 2021). This suggests semaglutide functions more as a chronic disease management tool than a short-term intervention — which has significant implications for treatment planning and cost sustainability.
Is it safe to get compounded semaglutide from online telehealth platforms?
Quality varies widely. Legitimate platforms require labs, have licensed providers review your medical history, and source from verified pharmacy facilities. Low-quality platforms may issue prescriptions without adequate clinical review or source from unverified compounders. Before using any telehealth service for semaglutide, ask specifically about their pharmacy source and quality controls — and ask to see a certificate of analysis for the batch you receive.
Bottom Line: Which Form Is Right for You?
Ozempic, Wegovy, and compounded semaglutide are all delivering the same GLP-1 receptor agonist to your system. The differences that matter are: your insurance coverage, your clinical indication, the dose you need to reach your goals, and whether you have access to a provider who can supervise your protocol properly.
For patients with type 2 diabetes and good commercial coverage, Ozempic is the straightforward choice. For patients with obesity who have commercial insurance covering Wegovy, that’s the on-label path. For the majority of people who don’t fit either of those profiles — or who are paying out of pocket — compounded semaglutide through a licensed provider is not a second-rate option. It’s often the only realistic path to access, and when properly sourced and monitored, it delivers the same clinical results.
Don’t start any semaglutide protocol without baseline labs. Don’t source compounded semaglutide outside a provider relationship. And don’t expect the medication to do all the work — the clinical evidence consistently shows that semaglutide works best as one component of a comprehensive metabolic health approach.
[INTERNAL-LINK: building a complete metabolic reset protocol → metabolic health comprehensive guide]
References
- Wilding JPH, et al. “Once-Weekly Semaglutide in Adults with Overweight or Obesity.” New England Journal of Medicine, 2021;384:989–1002. PMID: 33567185. https://www.nejm.org/doi/full/10.1056/NEJMoa2032183
- Garvey WT, et al. “Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial.” Nature Medicine, 2022;28:2083–2091. PMID: 36138325. https://www.nature.com/articles/s41591-022-02026-4
- Rubino DM, et al. “Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial.” NEJM, 2021;325(14):1414–1425. PMID: 34170647. https://www.nejm.org/doi/full/10.1056/NEJMoa2113290
- U.S. Food & Drug Administration. “Outsourcing Facility Information — Human Drug Compounding.” Retrieved 2026-07-03. https://www.fda.gov/drugs/human-drug-compounding/outsourcing-facility-information
- U.S. Food & Drug Administration. “FDA Drug Shortages — Semaglutide.” Retrieved 2026-07-03. https://www.accessdata.fda.gov/scripts/drugshortages/
- Davies M, et al. “Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, placebo-controlled, phase 3 trial.” The Lancet, 2021;397(10278):971–984. PMID: 33667417. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)00213-0/fulltext
- KFF Health Tracking. “Coverage and Use of Weight Loss Medications Among Adults.” 2024. https://www.kff.org/
This article is for educational and informational purposes only. It does not constitute medical advice. Consult a licensed healthcare provider before starting any medication, including semaglutide in any form. Individual results vary based on clinical factors, adherence, and lifestyle.